Xiaoling Song, Ph.D.
Affiliations: | 2010 | Biochemistry, Biophysics, and Molecular Biology | Iowa State University, Ames, IA, United States |
Area:
Genetics, Molecular Biology, Cell BiologyGoogle:
"Xiaoling Song"Parents
Sign in to add mentor| Marit Nilsen-Hamilton | grad student | 2010 | Iowa State | |
| (Plasminogen activator inhibitor 1: Mechanisms of its synergistic regulation by growth factors.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Truini A, Starrett JH, Stewart TF, et al. (2019) The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| McFadden DG, Politi K, Bhutkar A, et al. (2016) Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America |
| Song X, Fan PD, Bantikassegn A, et al. (2015) ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas. Cancer Research. 75: 1035-45 |
| Pirazzoli V, Nebhan C, Song X, et al. (2014) Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Reports. 7: 999-1008 |
| Pirazzoli V, Nebhan C, Song X, et al. (2013) Abstract C90: Dependence of afatinib and cetuximab resistant lung adenocarcinomas on mTOR signaling. Molecular Cancer Therapeutics. 12 |
| Song X, Fan P, Guha U, et al. (2013) Abstract C113: ERBB3 independent activation of the PI3K pathway in EGFR mutant lung adenocarcinomas. Molecular Cancer Therapeutics. 12 |
| Takezawa K, Pirazzoli V, Arcila ME, et al. (2012) HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discovery. 2: 922-33 |
| Song X, Thalacker FW, Nilsen-Hamilton M. (2012) Synergistic and multidimensional regulation of plasminogen activator inhibitor type 1 expression by transforming growth factor type β and epidermal growth factor. The Journal of Biological Chemistry. 287: 12520-8 |